Rottlerin promotes autophagy and apoptosis in gastric cancer cell lines

JUN SONG¹, YAN ZHOU¹², YU GONG¹, HANYANG LIU¹ and LIMING TANG¹

¹Department of Gastrointestinal Surgery; ²Medical Research Center, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu 213000, P.R. China

Received November 3, 2017; Accepted July 11, 2018

DOI: 10.3892/mmr.2018.9293

Abstract. It is widely accepted that apoptosis is closely associated with cancer cell death. However, whether closely induces tumor cell death has not been fully elucidated. Various studies have discussed the antitumor properties of rottlerin in human malignancies. The current study aimed to investigate the effects of rottlerin, a natural product isolated from the kamala tree (Mallotus philipensis), on growth inhibition and autophagy in gastric cancer (GC) cell lines in vitro. The results of the present study demonstrated that rottlerin suppressed cell growth, induced autophagy and apoptosis, and reduced migration and invasion in the SGC-7901 and MGC-803 GC cell lines. Furthermore, rottlerin led to microtubule-associated protein 1 light chain 3β-II augmentation and the enrichment of autophagosomes. In addition, the protein expression levels of mechanistic target of rapamycin kinase and S-phase kinase-associated protein 2 were downregulated in GC cells following rottlerin treatment, which is associated with autophagy. The protein levels of caspase-3, cleaved-caspase-3, total poly (ADP-ribose) polymerase (PARP) and cleaved-PARP exhibited no marked alterations in the GC cells following rottlerin treatment, indicating that caspases were likely not involved in rottlerin-induced GC apoptosis. In summary, the results of the present study indicate that rottlerin may inhibit invasion and promote apoptosis in GC cells, which may be mediated by the activation of autophagy. Therefore, rottlerin may be of value in the treatment of GC.

Introduction

Gastric cancer (GC) ranks fifth among all cancer types and is the third primary cause of cancer-associated mortality worldwide (1). Despite improvements in surgical and adjuvant therapies, the 5-year overall survival rate for patients with GC remains low; a poor prognosis is closely associated with the high metastasis and recurrence rate of GC. Furthermore, due to the development of drug resistance, as well as other factors, the benefits of chemotherapy and radiotherapy are limited (2,3). Therefore, there is a requirement for the development of novel treatment methods for GC.

It was previously demonstrated that 25-48% of the currently available Food and Drug Administration-approved medical treatments are derived from plants (4-6), and a number of these plant-derived compounds exhibit anticancer properties. Rottlerin, also referred to as mallotoxin, is a polyphenolic compound derived from the kamala tree (Mallotus philipensis) (7). Initial studies demonstrated that rottlerin is a protein kinase C δ (PKCδ) inhibitor (8-10). However, an increasing amount of evidence indicates that rottlerin may not only act as a specific PKCδ inhibitor, but that it has multiple molecular targets and anticancer properties, including the inhibition of cell proliferation, promotion of apoptosis and inhibition of cell migration and invasion (11-13). However, the exact molecular mechanisms underlying the actions and anticancer effects of rottlerin remain to be elucidated.

In eukaryotic cells, autophagy, which causes organelle and protein degradation, constitutes an adaptive response under conditions of starvation or cellular stress (14). It is necessary to recycle the unnecessary or dysfunctional organelles and the misfolded or damaged proteins through basal autophagy in order to maintain genomic integrity and cellular homeostasis (15). The activation of autophagy is implicated in a variety of stress conditions, whereas its dysregulation is implicated in numerous pathophysiological processes, including cardiovascular diseases and cancer (16). In cancer, autophagy may serve two opposing roles. Specifically, autophagy may act as a prosurvival mechanism when tumor cells are subjected to injury by chemical or physical treatment, but it may also promote cancer cell death, acting as a tumor suppressor (17). A previous study demonstrated that autophagy is constitutively activated in cancer in response to treatment and may be involved in therapy-triggered apoptosis. Therefore, it is
necessary to investigate the exact underlying mechanisms of autophagy in cancer (18).

Moretti et al (19) demonstrated that autophagy improved the effectiveness of anticancer therapy. Previous studies have demonstrated that rottlerin may promote apoptosis and autophagy in several types of cancer (20-22), but it remains unknown whether it exerts an anticancer effect on GC. To the best of our knowledge, the present study is the first to report antitumor effects of rottlerin on human GC cell lines. Furthermore, the molecular mechanism underlying the antitumor activity of rottlerin through activation of autophagy in GC cells was investigated, and the results indicate that rottlerin-induced autophagy may promote anticancer activity through cancer cell apoptosis.

Materials and methods

Cell culture and reagents. The SGC-7901 and MGC-803 human GC cell lines were purchased from the Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China. The cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) and 1% streptomycin and penicillin in a humidified incubator at 5% CO₂ and 37°C. Rabbit primary antibodies against S-phase kinase-associated protein 2 (Skp2; cat. no. ab183039), mechanistic target of rapamycin kinase (mTOR; cat. no. ab32028), microtubule-associated protein 1 light chain 3β (LC3)-II (cat. no. ab51520), caspase-3 (cat. no. ab13847), cleaved-caspase-3 (cat. no. ab2302), poly(ADP ribose) polymerase (PARP; cat. no. ab32138) and cleaved-PARP (cat. no. ab32064) were purchased from Abcam (Cambridge, UK). Rabbit primary antibodies against β-actin (cat. no. 4970) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Secondary antibody (goat anti-rabbit; cat. no. sc2004) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Rottlerin and dimethyl sulfoxide (DMSO) were acquired from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Rottlerin was dissolved in DMSO to generate a 10 mM stock solution. Cells cultured with only 0.1% DMSO served as the control group.

Cell proliferation assay. Cell proliferation was measured with a Cell Counting Kit-8 (CCK-8) assay (Dojindo Molecular Technologies, Inc., Kumamoto, Japan). SGC-7901 and MGC-803 cells were seeded in 96-well plates at a density of 1x10⁴ cells/well and incubated in a humid environment at 5% CO₂ and 37°C for 4 h. Subsequently, the cells were exposed to 0, 1, 2, 4, 8 and 16 µM rottlerin for 12, 24, 48 and 72 h. CCK-8 reagent was then added and incubated for 30 min at 37°C. Absorbance of the colored formazan product, formed by CCK-8 reagent was then added and incubated for 30 min at 37°C. Absorbance of the colored formazan product, formed by CCK-8 reagent at 450 nm.

Colony formation assay. SGC-7901 and MGC-803 cells were cultured in a 6-well plate at a density of 500 cells/well with 0, 2, 4 and 8 µM rottlerin at 37°C for 2 weeks. Cells treated with rottlerin-free medium served as the control group. After 2 weeks, the cells were fixed in 4% methanol for 15 min at room temperature. Cells were then stained with 0.1% crystal violet for 5 min at room temperature and imaged using a light microscope (Olympus Corporation, Tokyo, Japan) at x40 magnification.

Cell cycle assay. SGC-7901 and MGC-803 cells were seeded at a density of 1x10⁵/ml, and then harvested following treatment with 0, 2, 4 and 8 µM rottlerin at 37°C for 24 h. The cells were fixed in 70% ethanol at 4°C overnight. The fixed cells were centrifuged at 1,000 x g for 15 min at room temperature and washed with cold PBS three times. The cells were incubated with 50 μg/ml RNase A at 37°C for 30 min. Then cells were incubated with 100 μg/ml propidium iodide (PI) in the dark at 4°C for 30 min. The DNA content was quantified by FCM (BD CellQuest Pro; BD Biosciences, Franklin Lakes, NJ, USA). The percentages of cells in the G₀-G₁, S and G₂-M phases were compared with the control group.

Apoptosis assay. SGC-7901 and MGC-803 cells were cultured at 1x10⁵/ml in 6-well plates following treatment with 0, 2, 4 and 8 µM rottlerin at 37°C for 24 h. Cells were collected, washed twice with cold PBS and resuspended in 100 µL binding buffer containing 5 µL fluorescein isothiocyanate-conjugated anti-Annexin V antibody and 5 µL PI using a FITC-Annexin V Apoptosis Detection kit (BD Biosciences). Apoptosis was assessed using a FACS Calibur flow cytometer (BD CellQuest Pro; BD Biosciences). The percentages of apoptotic cells were compared with the control group.

Cell migration and invasion assays. SGC-7901 and MGC-803 cells were cultured at 1x10⁵/ml in 6-well plates. Migration was assessed using a wound healing assay that was performed following treatment with 0, 2, 4 and 8 µM rottlerin at 37°C for 0 and 24 h. A scratch was created in a culture plate using the tip of a pipette (Thermo Fisher Scientific, Inc.). Cells were incubated at 37°C and images were captured after 0 and 24 h. For the cell invasion assay, GC cells were incubated with 0, 2, 4 and 8 µM rottlerin at 37°C for 24 h and then harvested. 5x10⁴ cells were added to the upper chambers of a Transwell assay plate, which were coated with Matrigel, containing 200 µL serum-free medium. The lower chambers contained complete medium with 0, 2, 4 and 8 µM rottlerin. After 48 h, the cells in the lower chamber were fixed in cold methanol, stained with 0.1% crystal violet and images were captured.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. SGC-7901 and MGC-803 cells were incubated with 0, 2, 4 and 8 µM rottlerin at 37°C for 24 h. Total RNA was extracted using TRizol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. cDNA was synthesized using a PrimeScript™ RT Reagent kit (Takara Biotechnology Co., Ltd., Dalian, China) at 37°C for 15 min, followed by 85°C for 5 sec, determined at 4°C and gPCR was conducted using a SYBR® Premix Ex Taq™ kit (Takara Biotechnology Co., Ltd.) on a Bio-Rad iQ5 Real-Time PCR system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The following thermocycling conditions were used for the PCR: Initial denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. The primer sequences for amplification were as follows: mTOR, 5'-AGGGCCCATTTGCTCTATCAA-3' (forward) and 5'-GCAGTAAATGCGAGTATCATCCA-3' (reverse); Skp2,
5'-GCTGCTAAAGGTCTCTGGGT-3' (forward) and 5'-AGGCTTGAATTCTGCACCTTG-3' (reverse); and GAPDH, 5'-ACCAGAACTGTGGATGG-3' (forward) and 5'-CAGTGA GCTTCCCGTTCAG-3' (reverse). The relative expression was calculated using the 2-ΔΔCt method, with GAPDH used as the internal control (23).

Autophagy assay. SGC-7901 and MGC-803 cells were seeded in 96-well plates at a density of 2,000 cells/well in rottlerin-containing medium (0, 2, 4 and 8 µM rottlerin) at 37°C for 24 h, followed by incubation with the Autophagosomes Detection kit (Sigma-Aldrich; Merck KGaA). Medium was removed from the cells and 100 µl of the autophagosome detection reagent working solution was added to each well and cells were incubated at 37°C with 5% CO₂ for 30 min. Subsequently cells were washed with Wash Buffer 3 times by gently adding 100 µl of Wash Buffer to each well and cells were immediately imaged using a fluorescence microscope (Olympus Corporation, Tokyo, Japan). Autophagy was visualized as the bright blue staining of autophagic vacuoles.

Western blot analysis. Following treatment with 0, 2, 4 and 8 µM rottlerin at 37°C for 24 h, radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) was added for the extraction of proteins from GC cells for 40 min on ice. The supernatants incubated in 4°C for 30 min and centrifuged at 13,000 x g at 4°C for 15 min, the protein concentrations were measured by Enhanced BCA Protein Assay kit (Beyotime Institute of Biotechnology, Shanghai, China). Protein (20 µg) was loaded and separated via 12.5% SDS-PAGE, with a volume of 20 µl per well. The proteins were transferred onto 0.22-µm polyvinylidene fluoride membranes. The membranes were subsequently incubated with primary antibodies at a dilution of 1:1,000 at 4°C overnight, followed by incubation with secondary antibodies diluted in TBS-Tween-20 (0.1% Tween-20) at room temperature for 1.5 h. Enhanced chemiluminescence reagent (Pierce; Thermo Fisher Scientific, Inc.) was used to visualize the bound antibodies using the ChemiDoc imaging system (Abcam). Protein band intensities were semi-quantitated with ImageJ software (version 1.46r; National Institutes of Health, Bethesda, MD, USA) and normalized to β-actin.

Statistical analysis. Data are presented as the mean ± standard error. Each experiment was performed three times independently. Data analysis was performed by ANOVA using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA). Bonferroni's test was used as a post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

Rottlerin suppresses the proliferation of GC cells in a time- and dose-dependent manner. To investigate whether rottlerin suppressed the proliferation of GC cells, a CCK-8 assay was performed using SGC-7901 and MGC-803 cells following rottlerin treatment. The results demonstrated that rottlerin inhibited GC cell proliferation in a dose-dependent manner (Fig. 1A and B). Relative cell viability is presented in Fig. 1C. Rottlerin at 1 µM exerted no obvious suppressive effect on GC cells, 16 µM rottlerin caused cell death, and 2, 4 and 8 µM rottlerin was used as the experimental group.

Rottlerin on clonogenic capacity in GC cells. The colony formation assay revealed that rottlerin suppressed the clonogenic capacity of GC cells compared with the control group (Fig. 1D).

Rottlerin promotes apoptosis and cell cycle arrest in GC cells. It was previously reported that rottlerin promoted cell cycle arrest and apoptosis in breast cancer cells (11). To further elucidate the effects of rottlerin on cell cycle distribution and apoptosis in GC cells, the percentage of GC cells in each cell cycle phase following rottlerin treatment was determined through PI staining and flow cytometry. As presented in Fig. 2A and B, rottlerin led to evident G1/G0 phase arrest in GC cells. Rottlerin at 2, 4 and 8 µM led to a G1 cell population increase from 45.13±2.21% to 53.43±1.81, 60.45±3.07 and 66.79±1.94%, respectively, in SGC-7901 cells. Similarly, 2, 4 and 8 µM rottlerin caused a G0/G1 cell population increase from 42.21±1.86% to 50.41±1.87, 56.42±2.38 and 65.82±2.22%, respectively, in MGC-803 cells. Furthermore, flow cytometry following annexin V-FITC and PI staining revealed that, following treatment with rottlerin at 2, 4 and 8 µM, the apoptosis rate of MGC-803 cells were increased from 2.68±1.00% to 8.57±0.80, 12.27±1.06 and 15.19±0.92%, the SGC-7901 cell apoptosis rate from 3.20±1.60% to 16.01±1.15, 23.83±1.67 and 29.99±1.64%, respectively (Fig. 2C and D). Taken together, these results indicate that rottlerin promoted cell cycle arrest and apoptosis in GC cells.

Rottlerin inhibits the migration and invasion of GC cells. To determine the effects of rottlerin on the migratory activity of GC cells, a wound-healing assay was conducted. The results demonstrated that rottlerin inhibited migration in both types of GC cells in a dose-dependent manner (Fig. 3A and B). To confirm the effect of rottlerin on the invasion ability of GC cells, a Transwell assay was conducted using Matrigel (Fig. 3C and D). Rottlerin reduced the number of GC cells invading through the Matrigel, compared with the control group (Fig. 3C and D). These results indicate that rottlerin inhibited the migration and invasion ability of GC cells.

Effect of rottlerin on cell morphology. GC cells treated with 2, 4 and 8 µM rottlerin were examined under a light microscope (Fig. 4A). Cells treated with rottlerin were fewer compared with the control group, as well as smaller and more spindle-shaped, with less cytoplasm. Membrane ruffling was reduced, with a contractive cell appearance. Therefore, the morphology of GC cells treated with rottlerin was clearly affected. The observations were consistent with those in rat C6 glioblastoma cells, as reported by Parmer et al (24).

Rottlerin induces autophagy in GC cells. GC cells treated with 2, 4 and 8 µM rottlerin were used to investigate the association between rottlerin and autophagy. LC3-II expression levels were detected by western blotting and fluorescence microscopy was used to evaluate autophagosome formation. As demonstrated by examination with a fluorescence microscope, the number of autophagosomes was increased in the rottlerin-treated GC cells compared with the control group, as demonstrated.
SONG et al: ROTTLERIN PROMOTES AUTOPHAGY AND APOPTOSIS IN GASTRIC CANCER

by increased light blue fluorescence, whereas the light green cells were those without autophagosomes. (Fig. 4B). During autophagosome formation, the microtubule-associated LC3-I is converted to the membrane-bound form LC3-II (25).
LC3-II expression level was increased in GC cells following treatment with rottlerin and the quantitative results revealed significant differences compared with the control cells (Fig. 4C and D). Therefore, the results indicated that rottlerin may promote autophagy in GC cells.

Rottlerin causes apoptotic cell death independently of caspase. Rottlerin-induced apoptosis has been reported in several cancer cell lines (11,26). The caspase cascade functions in apoptosis induction and completion (27,28). Western blotting was conducted to evaluate caspase-3 and PARP expression, which exhibited no obvious increase in GC cells following treatment with rottlerin (Fig. 5). Cleaved-caspase-3 and PARP were also evaluated, and no cleaved-caspase-3 expression was detected in GC cells treated with rottlerin (Fig. 5). Cleaved-PARP was detected in GC cells, but the difference between rottlerin-treated GC cells and control cells was not statistically significant (Fig. 5). Similar observations were
reported by Torricelli et al (29). Therefore, rottlerin may promote apoptosis independently of caspase in GC cells.

**Rottlerin downregulates Skp2 and mTOR protein expression.**
Several studies have reported that rottlerin inhibits Skp2 protein expression in pancreatic and breast cancer (11,13). Wu et al (30) observed that Skp2 promoted autophagy through inhibition of mTOR complex 1 (mTORC1). The expression levels of mTOR and Skp2 were evaluated via RT-qPCR (Fig. 6A and B) and western blot assays (Fig. 6C-E) in GC cells treated with rottlerin. The mRNA levels of mTOR and Skp2 were downregulated following treatment with rottlerin for 24 h (Fig. 6A and B). The protein levels of mTOR and Skp2 following rottlerin treatment were consistent with the results for mRNA expression levels in GC cells (Fig. 6C-E). Consistent with previous studies, these results demonstrate that rottlerin may reduce the expression of Skp2 via the inhibition of mTOR expression in order to promote autophagy in GC cells (11,13).

**Discussion**

Due to the development of chemotherapy resistance, numerous phytochemical compounds derived from edible plants and their synthetic derivatives have attracted attention due to their unique anticancer properties and have been recommended for cancer therapy (31-33). However, information focusing on the anticancer properties of phytochemical compounds is limited; therefore, it is necessary to elucidate the mechanisms underlying their antitumor effects (34). The anticancer effects of phytochemical compounds are widely recognized, and phytochemicals may enhance the effectiveness of chemotherapy and decrease the toxic side effects (35,36). Rottlerin is a traditional Indian medicinal plant that was first identified as a PKCδ-selective inhibitor by Gschwendt et al (7) in 1994 and has been largely overlooked, despite its potential involvement in multiple signaling pathways. Further research demonstrated that rottlerin may inhibit several pathways in a PKCδ-independent manner. Basu et al (37) demonstrated that rottlerin was able to induce the apoptosis of HeLa cells through downregulation of caspase-2 via a PKCδ-independent pathway. Lin et al (12) reported that rottlerin inhibited follicular thyroid carcinoma cell migration independent of PKCδ.

Yin et al (11) reported that rottlerin exerted anticancer effects partially through Skp2 inactivation in breast cancer cells, while Su et al (13) demonstrated that rottlerin inhibited the proliferation and invasion of pancreatic cancer cells via the inactivation of Skp2. In addition, Zhao et al (38) demonstrated that rottlerin suppressed non-small-cell lung cancer through the downregulation of transcriptional co-activator with PDZ-binding motif. Similarly, the results of the current study revealed that rottlerin suppressed cancer cell proliferation, promoted apoptosis, and inhibited migration and invasion.

Apoptosis, a process that is crucial for the maintenance of normal tissue homeostasis, usually occurs as a consequence of either extracellular stimuli (extrinsic pathway) or intracellular stimuli (intrinsic or mitochondrial pathway) (39,40) and is closely associated with the design of chemotherapeutics. Shukla et al (41) observed that apigenin promoted the interaction between Ku70 and Bcl-2-associated X, and induced
prostate cancer cell apoptosis via apoptosis protein suppression. Caspases are involved in cell proliferation, migration, cytoskeletal organization and immunological effects (42,43). Disorders of the activity of caspases have been associated with multiple pathological processes, including cancer (44). Rottlerin may induce apoptosis through suppression of phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling or caspase cascade activation (45). The present study revealed no significant alterations in caspase-3, PARP, cleaved-caspase-3 and cleaved-PARP protein expression, indicating that rottlerin may promote apoptosis in GC cells through a caspase-independent pathway. Furthermore, the present results demonstrated that the percentage of SGC-7901 and MGC-803 cells in the G1 phase increased as the concentration of rottlerin increased, but there was no significant difference between the control and any rottlerin groups for S and G2 phases. It suggested that rottlerin may have caused cell cycle arrest in the G1 phase. And rottlerin may have enhanced the G1/S checkpoint activities and weakened the G2/M checkpoint activities, causing more SGC-7901 and MGC-803 cells to remain in G1 phase, and thus performing a function of preventing cell proliferation. But this needs to be verified with further experiments in future studies.

Autophagy, which involves the degradation of superfluous or damaged organelles and proteins, is an evolutionarily conserved lysosomal degradation process (46,47). Macroautophagy, chaperone-mediated autophagy and microautophagy, the major identified types of autophagy, vary in terms of delivery method of the cargo to the lysosome and physiological function (48). Autophagy is closely associated with cell survival, maintenance and various pathological processes, among which cancer has received the most attention (49-52). However, the role of autophagy in tumors remains controversial (53). Song et al (21) demonstrated that rottlerin induced autophagy and apoptotic cell death in human fibrosarcoma cells in a PKCδ-independent manner. In the present study, western blotting and autophagosome staining revealed that rottlerin promoted autophagy in a dose-dependent manner, indicating the potential anticancer function of rottlerin in GC.

The connection between apoptosis and autophagy has not been fully elucidated, however, a growing body of evidence indicates the presence of a molecular crosstalk between these two pathways (54,55). Our results demonstrated that rottlerin increased cell apoptosis and promoted autophagy, but future investigations should focus on the interplay of apoptosis and autophagy caused by rottlerin in GC. Several studies have demonstrated that rottlerin may inhibit cancer cell proliferation and progression via downregulation of the Skp2 protein (11,13). Wu et al (30) observed that Skp2 promoted autophagy through inhibition of mTORC1. Similarly, the present study identified Skp2 downregulation in GC cells following treatment with rottlerin. Kumar et al (20) demonstrated that rottlerin promoted apoptosis and autophagy in prostate cancer via PI3K/Akt/mTOR signaling. A similar result was reported by Singh et al (45) in pancreatic cancer. The present study demonstrated that the mRNA and protein levels of mTOR and Skp2 were both decreased following rottlerin treatment. It is not clear whether there is a connection between them, and this should be further investigated in future research. Future investigations should focus on the interplay of apoptosis and autophagy signaling pathways, as well as apoptosis pathways other than the caspase cascade. Furthermore, in vivo experiments are required to verify these results of rottlerin treatment observed in vitro.

In conclusion, to the best of our knowledge, the present study is the first to demonstrate that rottlerin induces apoptosis and autophagy in GC and, therefore, that treatment with rottlerin may be an effective approach to GC treatment.

Acknowledgements

Not applicable.
Funding
The present study was funded by the Changzhou Health and Family Planning Commission Project (grant nos. ZD201606 and QN201711) and the Nanjing Medical University School Fund (grant nos. 2016NJMUZD081 and 2017NJMU043).

Availability of data and materials
All data generated and analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions
JS and LT designed the study and wrote the manuscript. JS, YZ, YG and HL carried out the experiments and performed the statistical analysis. JS and YZ made contributions in modification the manuscript. All the authors have read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References


